BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/15/2023 12:44:08 AM | Browse: 131 | Download: 406
 |
Received |
|
2022-10-29 10:58 |
|
Peer-Review Started |
|
2022-10-29 11:01 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-12-30 05:22 |
|
Revised |
|
2023-01-02 14:44 |
|
Second Decision |
|
2023-01-20 03:30 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-01-23 18:04 |
|
Articles in Press |
|
2023-01-23 18:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-01-29 17:21 |
|
Typeset the Manuscript |
|
2023-02-07 06:43 |
|
Publish the Manuscript Online |
|
2023-02-15 00:44 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Prognostic value of Claudin 18.2 expression in gastric adenocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Erkan Kayikcioglu, Ramazan Oğuz Yüceer, Bulent Cetin, Kamuran Yüceer and Nermin Karahan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Erkan Kayikcioglu, MD, Assistant Professor, Department of Medical Oncology, Suleyman Demirel University, Cunur, Suleyman Demirel Caddesi, Isparta 32260, Türkiye. drkayikcioglu@yahoo.com |
| Key Words |
Gastric adenocarcinoma; Claudin 18.2; Overall survival; Clinicopathological characteristics |
| Core Tip |
Zolbetuximab is a new antibody drug targeting the cell surface protein claudin 18.2 (CLDN 18.2) expressed by gastric cancer cells. CLDN 18.2 expression, identifying the patient population who are susceptible to zolbetuximab, is discordant in different studies. The present study aimed to research the expression ratio of CLDN and its prognostic value for overall survival in patients with gastric adenocarcinoma in a single center located in Turkey. |
| Publish Date |
2023-02-15 00:44 |
| Citation |
Kayikcioglu E, Yüceer RO, Cetin B, Yüceer K, Karahan N. Prognostic value of Claudin 18.2 expression in gastric adenocarcinoma. World J Gastrointest Oncol 2023; 15(2): 343-351 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i2/343.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i2.343 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
